// App-Quantinova.ai

1080 : Comparison Of Two Dosing Schedules For Subcutaneous Injections Of Low-Dose Anti-CD20 Veltuzumab In Relapsed Immune Thrombocytopenia: Final Results Of a Phase I Study

Researchers

Presenter

  • Howard Liebman

Principal Investigators

  • James B Bussel

  • Mansoor N Saleh

  • Heather Horne

  • William A Wegener

  • David M Goldenberg

Medical Centers

  • Georgia Cancer Spclsts PC, Atlanta, GA

  • Jane Anne Nohl Division of Hematology, Keck School Of Medicine of USC, Los Angeles, CA

  • Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY

Locations

  • United States

Companies

  • Immunomedics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Immune thrombocytopenia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Thrombocytopenia

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Circulating tumor cells

  • Cluster of Differentiation 19

  • Transthyretin

Drug/Treatment

  • HA20

  • Oraprine

  • Veltucyn (IV)

  • Rituximab

  • Danazol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved